Trials / Withdrawn
WithdrawnNCT06354101
The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.
The VITALITY Registry
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- CorEvitas · Network
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this registry study is to learn more about metabolic health. The information gathered will be used to support research on the natural history of obesity and weight related diseases, their treatments, and how it affects overall health. Approximately 15,000 participants who are overweight or have obesity with or without metabolic diseases are expected to participate in this registry study.
Detailed description
The VITALITY Registry is a research study to collect healthcare information on people with conditions related to their weight which is stored in a database. Participants, along with their doctor, provide the health information that makes up this database. Participants will not be asked to take any special treatments or tests as part of the study. Participants will be asked to complete questionnaires 2 times a year for up to 10 years, and the doctor will be asked to enter certain available information from office visits 1 time per year for up to 10 years regarding health, treatments, and symptoms related to the participants metabolic health. The information that will be collected for this study will include demographics (for example, age, gender, race, employment, etc.), medical history (including all prior and current treatments), social history, details about your metabolic health, how metabolic health impacts daily life, mental health, and satisfaction with treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Once-weekly subcutaneous injectable |
| DRUG | Semaglutide | Once-weekly subcutaneous injectable |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2023-07-01
- Completion
- 2023-07-01
- First posted
- 2024-04-09
- Last updated
- 2024-04-09
Source: ClinicalTrials.gov record NCT06354101. Inclusion in this directory is not an endorsement.